Danske Bank A S Grows Stock Position in Edwards Lifesciences Corporation $EW

Danske Bank A S grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 346,523 shares of the medical research company’s stock after purchasing an additional 32,200 shares during the quarter. Danske Bank A S’s holdings in Edwards Lifesciences were worth $29,541,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Vanguard Group Inc. boosted its stake in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after purchasing an additional 365,581 shares during the period. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Jennison Associates LLC boosted its position in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

EW opened at $84.08 on Friday. The business’s 50-day moving average is $82.08 and its two-hundred day moving average is $82.47. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $48.47 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.11 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the previous year, the firm earned $0.64 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on EW. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Wells Fargo & Company raised their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $95.65.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the sale, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 86,058 shares of company stock worth $7,118,636. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.